CARSGEN-B (02171) issued a profit warning, expecting that the net loss in 2025 will decrease by no more than approximately 120 million yuan compared to the previous year.

CARSGEN-B (02171) announces that, based on the preliminary assessment of the unaudited management accounts of the Group for the year ending December 31, 2025 (reporting period) and the information currently available to the Board of Directors, the Group expects to incur a net loss and a decrease in adjusted net loss compared to the same period last year. Details are as follows: (a) the net loss for the reporting period is expected to be approximately RMB 1.2 billion, compared to approximately RMB 7.98 billion for the year ending December 31, 2024; and (b) the adjusted net loss for the reporting period (excluding share-based compensation expenses) is expected to be approximately RMB 95 million, compared to approximately RMB 7.89 billion for the year ending December 31, 2024. The reduction in losses is mainly attributed to the following factors: (i) increased commercial revenue of Zevokiorun Injection in mainland China; (ii) the impact of foreign exchange fluctuations; and (iii) significant reduction in research and development expenses for Zevokiorun Injection and Suregioorun Injection.